|
| Year | Number of patients | Study type | Methodology | Key findings |
|
| 2000 [23] | Uremic patients (n = 28) and renal transplant patients (n =14) | Cross-sectional study | (1-84) PTH was detected by a new IRMA assay and iPTH assay was purchased from the Nichols Institute (I-Nichols, San Juan Capistrano, CA, USA). | In CKD patients, the presence of high circulating levels of non-(1-84) PTH fragments (most likely (7-84) PTH) detected by the “intact” assay and the antagonistic effects of (7-84) PTH on the biological activity of (1-84) PTH explain the need of higher levels of “intact” PTH to prevent adynamic bone disease. |
|
| 2004 [24] | PHPT patients (n = 74) and SHPT patients (n =18) who underwent PTX | Cross-sectional study | iPTH and (1-84) PTH were detected both by 2-site immunochemiluminometric assay. | Plasma (1-84) PTH decreased more rapidly than iPTH after PTX in patients in both the PHPT and SHPT groups, which suggested that a quick (1-84) PTH assay may be a more useful adjunct to PTX in both SHPT and PHPT. |
|
| 2008 [25] | Dialysis patients (n =515) | Cohort study | Scantibodies Clinical Laboratory (SCL; Santee, CA, USA) was responsible for measuring iPTH and (1-84) PTH, no detailed methodology was discussed. | The circulating levels of (1-84) PTH and iPTH were highly correlated.
Elevated levels of (1-84) PTH was significantly associated with increased mortality, whereas iPTH did not reach statistical significance. |
|
| 2010 [26] | A SHPT patient with cinacalcet therapy | Case report | Detailed methods for measuring iPTH and (1-84) PTH were not mentioned. | This patient had abnormally higher (1-84) PTH levels than iPTH levels and (1-84) PTH/iPTH ratio was reversed by cinacalcet therapy. |
|
| 2011 [9] | Hemodialysis patients (n =53) | Cohort study | Elecsys iPTH and (1-84) PTH assay were measured by ECLIA, and Whole PTH assay was measured by IRMA. | The Elecsys (1-84) PTH assay provides comparable data to the Whole PTH assay for monitoring parathyroid function in patients receiving hemodialysis. |
|
| 2011 [15] | Patients with varying stages of CKD (n =203) | Cross-sectional study | iPTH and (1-84) PTH were measured both by immunoassay. | iPTH, (1-84) PTH, and (7-84) PTH increase with increasing CKD stages, with a relatively greater increase in (7-84) PTH. |
|
| 2011 [17] | Hemodialysis patients (n =738) | Cross-sectional study | (1-84)PTH was detected by immunoradiometric assay and method for measuring iPTH was not mentioned. | As the circulating PTH levels increased, there was a large difference between the iPTH and (1-84) PTH assays. Twenty-eight percent of the total population was misclassified within an iPTH target range of the Japanese guidelines. |
|
| 2011 [27] | Hemodialysis patients (n =70) | Cohort study | iPTH and (1-84) PTH were measured by Nichols Advantage Intact PTH and Nichols Bio-Intact PTH Chemiluminescence Assays respectively. | A higher (1-84) PTH /non-(1-84) PTH ratio is associated with an increased risk for cardiovascular events in hemodialysis patients. |
|
| 2013 [28] | Male hemodialysis patients (n =177) | Cohort study | iPTH was measured by electrochemiluminescence immunoassay, and (1-84) PTH was detected by two-site IRMA assay. | The higher group in (1-84) PTH/iPTH ratio had significantly higher all-cause mortality than the lower group. |
|
| 2014 [11] | Patients on peritoneal dialysis (PD) (n =73) | Cross-sectional study | PTH was quantified by six second generation assays (one isotopic and five chemiluminescence assays) and by one third generation PTH method (IRMA assay). | PD patients have a higher proportion of (7-84) PTH circulating fragments than hemodialysis patients assessed previously. |
|
| 2015 [13] | Adult dialysis patients with cinacalcet therapy (n =44) and without (n =112) | Cohort study | iPTH was detected by an electrochemiluminescence immunocomparable assay, and (1-84) PTH was detected by an immunoradiometric assay. | The (1-84) PTH/iPTH ratio in cinacalcet users is lower than that in the non-users with comparable levels of serum Ca. |
|
| 2017 [29] | Hemodialysis patients (n =145) | Cohort study | iPTH and (1-84) PTH were both detected by an electrochemiluminescence method. | Didn't find any advantages to using (1-84) PTH vs. iPTH as a marker of mortality. (1-84) PTH limits of normality must be reevaluated because its relationship with iPTH is not consistent. |
|
| 2018 [30] | Stage 5 CKD patients (n =262) including those who underwent PTX (n =92) | Cross-sectional and cohort study | iPTH and (1-84) PTH were both measured by ECLIA method. | Stage 5 CKD patients had higher plasma levels of different PTH fragments, and lower (1-84) PTH/iPTH ratio. PTX could significantly reverse these abnormalities in severe SHPT patients. |
|
